Bachem Holding AGBCHMF 91 EBIT per Share is $2.60 as of Dec. 2025. GuruFocus rates BCHMF with a GF Score™ of 91/100 and a GF Value™ of $116.99 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,181 Biotechnology companies, Bachem Holding AG ranks worse than 57.92% on this metric.
Bachem Holding AG's EBIT per Share for the
six
months ended in Dec. 2025 was $1.68.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $2.60.
During the past 12 months, the average EBIT per Share Growth Rate of Bachem Holding AG was 25.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 9.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 6.90% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 15.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Bachem Holding AG's EBIT per Share or its related term are showing as below:
BCHMF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -40.3 Med: 12.4 Max: 31.1
Current: 9
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Bachem Holding AG was 31.10% per year. The lowest was -40.30% per year. And the median was 12.40% per year.
BCHMF's 3-Year EBIT Growth Rate is ranked worse than 57.92% of 1181
companies
in the Biotechnology industry
Industry Median: 15.5
vs BCHMF: 9.00
Bachem Holding AG (OTCPK:BCHMF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Bachem Holding AG EBIT per Share Related Terms
Bachem Holding AG EBIT per Share Historical Data
* Premium members only.
The historical data trend for Bachem Holding AG's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $2.60
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bachem Holding AG (BCHMF) has a EBIT per Share of $2.60 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bachem Holding AG and its competitors. According to the industry distribution chart, Bachem Holding AG ranks #684 out of 1181 companies in the Biotechnology industry, placing it in the top 57.9%.
Is Bachem Holding AG's EBIT per Share too high?
Bachem Holding AG's current EBIT per Share is $2.60. The Biotechnology industry median EBIT per Share is 15.50. Bachem Holding AG's value of $2.60 is 83.2% below this industry median. Based on the distribution chart, Bachem Holding AG ranks #684 out of 1181 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bachem Holding AG has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bachem Holding AG's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bachem Holding AG ranks #684 out of 1181 companies for EBIT per Share. This places Bachem Holding AG in the lower half of its industry. The industry median EBIT per Share is 15.50. Bachem Holding AG's value of $2.60 is 83.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,181 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bachem Holding AG's current EBIT per Share of $2.60 is 83.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bachem Holding AG and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bachem Holding AG's current EBIT per Share is $2.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bachem Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Bachem Holding AG (BCHMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $116.99, compared to a current price of $87.34 — trading 25.3% below its estimated fair value. The current EBIT per Share is $2.60 and 83.2% below the Biotechnology industry median of 15.50. Bachem Holding AG's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Bachem Holding AG (BCHMF), the current EBIT per Share is $2.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bachem Holding AG (BCHMF) Overvalued in 2026?
Based on GuruFocus' analysis, Bachem Holding AG stock appears to be undervalued.
The current stock price of $87.34 is trading 25.3% below its estimated GF Value™ of $116.99.
GuruFocus considers Bachem Holding AG to be Modestly Undervalued.
Key valuation signals for BCHMF:
EBIT per Share: $2.60
GF Value™: $116.99 vs. price of $87.34 (25.3% below fair value)
Industry Position: 83.2% below the Biotechnology median (#684 of 1181)
No single metric tells the full story. See the BCHMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities. Geographically, it operates in Switzerland, USA, Ireland, Denmark, United Kingdom, and Rest of the World.
91GF Score
Get the complete analysis for BCHMF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCHMF has been successfully added to your 
